Lunit , a global leader in AI-driven cancer diagnostics and precision oncology, has partnered with Labcorp, a major innovator in clinical and pathology services, to advance the use of digital pathology (DP) and artificial intelligence (AI) in oncology research and clinical practice.
Through this collaboration, the two organizations aim to integrate Labcorp’s deep clinical and pathology expertise with Lunit’s advanced AI technology to reshape how tumor microenvironments are evaluated. By combining high-resolution whole-slide imaging with AI-supported spatial profiling, the initiative seeks to unlock new insights that could accelerate biomarker discovery and support more precise immuno-oncology approaches.
Early Collaborative Studies Debut at SITC and AMP
The partnership’s first joint findings were presented at two major scientific forums:
· Society for Immunotherapy of Cancer (SITC):
The study demonstrated that AI-driven spatial profiling and machine learning can help identify immune-active subtypes of non-small cell lung cancer (NSCLC) harboring the MET exon 14 skipping mutation—subtypes linked with better responses to immunotherapy. Using Lunit SCOPE IO®, researchers evaluated over 370 pathology slides to categorize immune phenotypes across various MET alterations, including exon 14 skipping, amplification, and wildtype. Further immune gene expression analysis confirmed these AI-derived immune phenotypes and highlighted key immune response pathways associated with the inflamed signature, reinforcing the predictive value of AI-enabled spatial profiling in MET-mutated NSCLC.
· Association for Molecular Pathology (AMP):
Findings revealed contrasting tumor-immune microenvironments across MET alterations in NSCLC, showing immune-desert patterns in MET-amplified tumors and inflamed profiles in tumors with MET exon 14 skipping.
“Collaborating with Labcorp, one of the most respected leaders in diagnostics and clinical research, marks an important step toward expanding the real-world use of AI in oncology. These early studies show how AI can reveal meaningful, predictive biomarkers hidden within pathology slides,” said Brandon Suh, CEO of Lunit. “It’s a clear example of how digital pathology and AI can work hand in hand to advance precision oncology understanding, bridging discovery research and real-world clinical care.”
“Our collaboration with Lunit aims to turn complex pathology data into meaningful insights,” said Shakti Ramkissoon, M.D., Ph.D., MBA, vice president and medical lead for oncology at Labcorp. “These studies demonstrate how AI-powered digital pathology can reveal patterns within tumors—ultimately helping to guide treatment decisions, inform biomarker development, and pave the way for more personalized cancer care.”
Building on these early successes, Labcorp and Lunit intend to expand the use of digital pathology AI across additional cancer types and explore deeper genomic correlations to further strengthen precision oncology applications.
